GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » Shares Outstanding (Diluted Average)

Biocept (Biocept) Shares Outstanding (Diluted Average) : 1.04 Mil (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biocept Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Biocept's average diluted shares outstanding for the quarter that ended in Jun. 2023 was 1.04 Mil.


Biocept Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Biocept's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Shares Outstanding (Diluted Average) Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.07 0.40 0.49 0.57

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.57 0.57 0.59 1.04

Biocept Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Biocept  (OTCPK:BIOCQ) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Biocept Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Biocept's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (Biocept) Business Description

Traded in Other Exchanges
N/A
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Executives
Robert Walsh officer: VP, Controller 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock director C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand officer: Chief Operations Officer C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor officer: Sr. V.P., General Counsel C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale director, officer: EXECUTIVE CHAIRMAN 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales director C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein director 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan officer: Chief Med Off & Med. Director 2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory officer: Sr. VP Corp. Development C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick officer: SVP, Chief Commercial Officer 2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry officer: Sr VP Comm. Operations
Marsha Alpert Chandler director 7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall director, officer: CEO AND PRESIDENT 4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy officer: CFO, Sr V.P. Operations & Sec. 5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121